Integer (NYSE:ITGR) Now Covered by Raymond James

Equities research analysts at Raymond James initiated coverage on shares of Integer (NYSE:ITGR) in a report issued on Friday, Marketbeat reports. The firm set an “outperform” rating and a $145.00 price target on the medical equipment provider’s stock. Raymond James’ price target would indicate a potential upside of 23.83% from the stock’s previous close.

Several other research firms have also recently issued reports on ITGR. Citigroup boosted their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Truist Financial boosted their price objective on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Benchmark raised their target price on shares of Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Wells Fargo & Company reiterated an “overweight” rating and set a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. Finally, KeyCorp raised their price objective on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $148.56.

Integer Stock Performance

Shares of ITGR stock opened at $117.09 on Friday. The company has a market capitalization of $3.94 billion, a P/E ratio of 34.85, a PEG ratio of 1.72 and a beta of 1.24. Integer has a fifty-two week low of $107.11 and a fifty-two week high of $146.36. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The stock has a 50 day moving average price of $130.47 and a two-hundred day moving average price of $132.03.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $449.50 million for the quarter, compared to analysts’ expectations of $446.28 million. Analysts expect that Integer will post 6.01 earnings per share for the current year.

Institutional Trading of Integer

Hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. increased its position in Integer by 4.4% during the 4th quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock valued at $220,000 after buying an additional 71 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Integer by 0.9% during the fourth quarter. Arizona State Retirement System now owns 9,732 shares of the medical equipment provider’s stock valued at $1,290,000 after acquiring an additional 84 shares in the last quarter. HighTower Advisors LLC raised its position in shares of Integer by 0.8% in the 3rd quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock worth $1,579,000 after purchasing an additional 90 shares during the last quarter. HighPoint Advisor Group LLC boosted its stake in Integer by 6.4% in the 4th quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 101 shares in the last quarter. Finally, Norden Group LLC grew its position in Integer by 7.0% during the 4th quarter. Norden Group LLC now owns 1,668 shares of the medical equipment provider’s stock valued at $221,000 after purchasing an additional 109 shares during the last quarter. 99.29% of the stock is owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.